Breast cancer survival among economically disadvantaged women: The influences of delayed diagnosis and treatment on mortality

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 10, 2008, Pages 2882-2890

  Smith, Emily Rose ^a,b,e   Adams, Swann Arp ^a,b   Das, Irene Prabhu ^d   Bottai, Matteo ^a   Fulton, Jeanette ^c   Hebert, James R ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b South Carolina Statewide Cancer Prevention and Control Program   (United States)

^c Palmetto Richland Memorial Hospital   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR;

ADULT; AFRICAN AMERICAN; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; DELAYED DIAGNOSIS; ECONOMIC ASPECT; EUROPEAN AMERICAN; FEMALE; HEALTH PROGRAM; HUMAN; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE DIFFERENCE; RANK SUM TEST; UNITED STATES;

AFRICAN AMERICANS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SOCIOECONOMIC FACTORS; SOUTH CAROLINA; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 54249122301     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0221     Document Type: Article

References (62)

1. Adams SA, Hebert JR, Bolick-Aldrich S, et al. Breast cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology. J S C Med Assoc 2006;102:231-9.
2. Dansey RD, Hessel PA, Browde S, et al. Lack of a significant independent effect of race on survival in breast cancer. Cancer 1988;61:1908-12.
3. Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA 1994;272:947-54.
4. Newman LA. Breast cancer in African-American women. Oncologist 2005;10:1-14.
5. Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 2003;97:134-47.
6. Feig SA. Role and evaluation of mammography and other imaging methods for breast cancer detection, diagnosis, and staging. Semin Nucl Med 1999;29:3-15.
7. Marbella AM, Layde PM. Racial trends in age-specific breast cancer mortality rates in US women. Am J Public Health 2001;91:118-21.
8. McCarthy EP, Burns RB, Coughlin SS, et al. Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women. Ann Intern Med 1998;128:729-36.
9. Rosenquist CJ, Lindfors KK. Screening mammography beginning at age 40 years: a reappraisal of cost-effectiveness. Cancer 1998;82:2235-40.
10. Shapiro S, Smart C. Organizing systems for breast cancer detection. Cancer 1989;64:2698.
11. Wojcik BE, Spinks MK, Optenberg SA. Breast carcinoma survival analysis for African American and white women in an equal-access health care system. Cancer 1998;82:1310-8.
12. Olsen O, Gotzsche PC. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2001:CD001877.
13. Rolnick SJ, O'Connor PJ, Jackson JM, Boyle RG, Pronk NP, Loes LM. Early- and late-stage breast cancer in a managed care setting in relation to mammography screening. Cancer Detect Prev 1998;22:495-8.
14. Charlson ME. Delay in the treatment of carcinoma of the breast. Surg Gynecol Obstet 1985;160:393-9.
15. Elwood JM, Moorehead WP. Delay in diagnosis and long-term survival in breast cancer. Br Med J 1980;280:1291-4.
16. Huguley CM, Jr., Brown RL, Greenberg RS, Clark WS. Breast self-examination and survival from breast cancer. Cancer 1988;62:1389-96.
17. Machiavelli M, Leone B, Romero A, et al. Relation between delay and survival in 596 patients with breast cancer. Oncology 1989;46:78-82.
18. Neave LM, Mason BH, Kay RG. Does delay in diagnosis of breast cancer affect survival? Breast Cancer Res Treat 1990;15:103-8.
19. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999;353:1119-26.
20. Rossi S, Cinini C, Di Pietro C, et al. Diagnostic delay in breast cancer: correlation with disease stage and prognosis. Tumori 1990;76:559-62.
21. Sainsbury R, Johnston C, Haward B. Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis. Lancet 1999;353:1132-5.
22. Sheridan B, Fleming J, Atkinson L, Scott G. The effects of delay in treatment of survival rates in carcinoma of the breast. Med J Aust 1971;1:262-7.
23. Wilkinson GS, Edgerton F, Wallace HJ, Jr., Reese P, Patterson J, Priore R. Delay, stage of disease and survival from breast cancer. J Chronic Dis 1979;32:365-73.
24. Afzelius P, Zedeler K, Sommer H, Mouridsen HT, Blichert-Toft M. Patient's and doctor's delay in primary breast cancer. Prognostic implications. Acta Oncol 1994;33:345-51.
25. Raabe NK, Fossaa SD. Primary invasive breast carcinoma in Oslo 1980-1989. Incidence and delay. Acta Oncol 1996;35:9-15.
26. Elmore JG, Nakano CY, Linden HM, Reisch LM, Ayanian JZ, Larson EB. Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment. Med Care 2005;43:141-8.
27. Gorin SS, Heck JE, Cheng B, Smith SJ. Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med 2006;166:2244-52.
28. Taplin SH, Ichikawa L, Yood MU, et al. Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up? J Natl Cancer Inst 2004;96:1518-27.
29. American College of Radiology. Breast imaging reporting and data system. 2nd ed. Reston, VA: American College of Radiology; 1995.
30. Young JJ, Roffers S, Ries L, Fritz A, Hurlbut A. SEER summary staging manual-2000: codes and coding instruction. Bethesda (MD): National Cancer Institute, NIH; 2001.
31. SAS Institute, Inc. SAS system for Windows V9.1. 9 ed. ed. Cary (NC): SAS Institute; 2004.
32. Bridge PD, Sawilowsky SS. Increasing physicians' awareness of the impact of statistics on research outcomes: comparative power of the t-test and Wilcoxon rank-sum test in small samples applied research. J Clin Epidemiol 1999;52:229-35.
33. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
34. Cox D. Regression models and life tables (with discussion). J R Stat Soc Ser B 1972;34:187-220.
35. Allison P. Survival analysis using the SAS system: a practical guide. Cary (NC): SAS Institute; 1995.
36. Caplan LS, Helzlsouer KJ, Shapiro S, Wesley MN, Edwards BK. Reasons for delay in breast cancer diagnosis. Prev Med 1996;25:218-24.
37. Caplan LS, May DS, Richardson LC. Time to diagnosis and treatment of breast cancer: results from the National Breast and Cervical Cancer Early Detection Program, 1991-1995. Am J Public Health 2000;90:130-4.
38. Coates RJ, Bransfield DD, Wesley M, et al. Differences between black and white women with breast cancer in time from symptom recognition to medical consultation. Black/White Cancer Survival Study Group. J Natl Cancer Inst 1992;84:938-50.
39. Dennis CR, Gardner B, Lim B. Analysis of survival and recurrence vs. patient and doctor delay in treatment of breast cancer. Cancer 1975;35:714-20.
40. McCarthy BD, Yood MU, Boohaker EA, Ward RE, Rebner M, Johnson CC. Inadequate follow-up of abnormal mammograms. Am J Prev Med 1996;12:282-8.
41. Chen VW, Correa P, Kurman RJ, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 1994;3:127-35.
42. Cunningham JE, Butler WM. Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat 2004;88:161-76.
43. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994;86:705-12.
44. Natarajan N, Nemoto T, Mettlin C, Murphy GP. Race-related differences in breast cancer patients. Results of the 1982 national survey of breast cancer by the American College of Surgeons. Cancer 1985;56:1704-9.
45. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
46. Crowe JP, Jr., Gordon NH, Hubay CA, Pearson OH, Marshall JS, McGuire WL. The interaction of estrogen receptor status and race in predicting prognosis for stage I breast cancer patients. Surgery 1986;100:599-605.
47. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007;110:876-84.
48. Gwyn K, Bondy ML, Cohen DS, et al. Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer 2004;100:1595-604.
49. Vernon SW, Tilley BC, Neale AV, Steinfeldt L. Ethnicity, survival, and delay in seeking treatment for symptoms of breast cancer. Cancer 1985;55:1563-71.
50. Gardner B. The relationship of delay in treatment to prognosis in human cancer. Prog Clin Cancer 1978;7:123-33.
51. Gregorio DI, Cummings KM, Michalek A. Delay, stage of disease, and survival among White and Black women with breast cancer. Am J Public Health 1983;73:590-3.
52. Burgess CC, Ramirez AJ, Richards MA, Love SB. Who and what influences delayed presentation in breast cancer? Br J Cancer 1998;77:1343-8.
53. McCarthy BD, Yood MU, Janz NK, Boohaker EA, Ward RE, Johnson CC. Evaluation of factors potentially associated with inadequate follow-up of mammographic abnormalities. Cancer 1996;77:2070-6.
54. Ramirez AJ, Westcombe AM, Burgess CC, Sutton S, Littlejohns P, Richards MA. Factors predicting delayed presentation of symptomatic breast cancer: a systematic review. Lancet 1999;353:1127-31.
55. Weinmann S, Taplin SH, Gilbert J, et al. Characteristics of women refusing follow-up for tests or symptoms suggestive of breast cancer. J Natl Cancer Inst Monogr 2005;35:33-8.
56. Potter JD, Cerhan JR, Sellers TA, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 1995;4:319-26.
57. Emi Y, Kitamura K, Shikada Y, Kakeji Y, Takahashi I, Tsutsui S. Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis. Surgery 2002;131:S217-21.
58. Menard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 2004;61:2965-78.
59. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003;22:6570-8.
60. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006;8:215.
61. Wu Y, Mohamed H, Chillar R, et al. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res 2008;10:R3.
62. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer 2008 Mar 29 [Epub ahead of print].